MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-11-2026
Bristol-Myers Squibb Company Market Cap 2011-2026 | BMY
As of March 02, 2026 Bristol-Myers Squibb Company has a market cap of $ 127 B
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Bristol-Myers Squibb Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122 B | 114 B | 100 B | 154 B | 151 B | 133 B | 144 B | 79.8 B | 105 B | 81.4 B | 104 B | 99.9 B | 83 B | 61.2 B | 54.8 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 154 B | 54.8 B | 106 B |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acer Therapeutics
ACER
|
12.1 M | - | 2.71 % | $ 14 M |  USA |
 |
AbbVie
ABBV
|
400 B | $ 232.08 | 3.29 % | $ 411 B | USA |
 |
AbCellera Biologics
ABCL
|
962 M | $ 3.61 | 0.56 % | $ 1.08 B |  Canada |
 |
Abeona Therapeutics
ABEO
|
149 M | $ 5.12 | -1.54 % | $ 109 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
445 M | $ 4.66 | -0.85 % | $ 773 M | Canada |
 |
ACADIA Pharmaceuticals
ACAD
|
3.19 B | $ 24.56 | -0.32 % | $ 4.07 B | USA |
 |
I-Mab
IMAB
|
127 M | - | - | $ 866 M |  China |
 |
Achieve Life Sciences
ACHV
|
90.2 M | $ 4.56 | -3.59 % | $ 90.4 M | USA |
 |
AC Immune SA
ACIU
|
305 M | $ 2.93 | -1.01 % | $ 229 M |  Schweiz |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | USA |
 |
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aclaris Therapeutics
ACRS
|
385 M | $ 2.87 | -8.31 % | $ 352 M | USA |
 |
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | USA |
 |
Adagene
ADAG
|
87.8 M | $ 2.96 | -4.67 % | $ 167 M | China |
 |
ADC Therapeutics SA
ADCT
|
1.22 B | $ 4.1 | -0.73 % | $ 105 M | Schweiz |
 |
Adial Pharmaceuticals
ADIL
|
5.05 M | $ 2.53 | - | $ 16.4 M | USA |
 |
ADMA Biologics
ADMA
|
3.78 B | $ 15.57 | 2.57 % | $ 3.71 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | - | - | $ 26.5 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
2.48 B | $ 16.02 | -2.67 % | $ 2.43 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | USA |
 |
ADiTx Therapeutics
ADTX
|
59.2 K | $ 0.46 | -4.63 % | $ 6.06 K | USA |
 |
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Agenus
AGEN
|
215 K | $ 3.33 | -0.89 % | $ 1.19 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
1.63 B | $ 30.23 | 0.83 % | $ 1.75 B | USA |
 |
AIM ImmunoTech
AIM
|
20.2 M | $ 0.91 | -8.59 % | $ 43.8 M | USA |
 |
Akebia Therapeutics
AKBA
|
334 M | $ 1.31 | -0.76 % | $ 337 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
79.3 B | $ 0.24 | -8.87 % | $ 5.73 B | Britain |
 |
ARCA biopharma
ABIO
|
484 M | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
40.7 M | - | 4.01 % | $ 150 M | Canada |
 |
Aldeyra Therapeutics
ALDX
|
327 M | $ 5.46 | -0.73 % | $ 328 M | USA |
 |
Alector
ALEC
|
247 M | $ 2.43 | -5.08 % | $ 250 M | USA |
 |
Aligos Therapeutics
ALGS
|
55.9 M | $ 7.03 | -6.27 % | $ 452 M | USA |
 |
Adverum Biotechnologies
ADVM
|
76.4 M | - | - | $ 86.2 M | USA |
 |
Alkermes plc
ALKS
|
5.13 B | $ 30.1 | -2.05 % | $ 4.96 B |  Irlanda |
 |
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - |  Russia |
 |
Allogene Therapeutics
ALLO
|
706 M | $ 2.78 | 1.83 % | $ 436 M | USA |
 |
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
40.8 B | $ 332.92 | 0.51 % | $ 43.6 B | USA |
 |
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
172 M | - | 0.23 % | $ 488 M | USA |
 |
Altimmune
ALT
|
463 M | $ 4.31 | -3.36 % | $ 306 M | USA |
 |
Albireo Pharma
ALBO
|
538 M | - | -0.23 % | $ 916 M | USA |
 |
ALX Oncology Holdings
ALXO
|
76.2 M | $ 2.11 | -10.21 % | $ 110 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
71.4 M | - | 3.16 % | $ 1.9 M | USA |
 |
Amgen
AMGN
|
198 B | $ 388.16 | 2.33 % | $ 209 B | USA |
 |
Aileron Therapeutics
ALRN
|
38.2 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
49 M | - | 4.14 % | $ 49.1 M | USA |